Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 12, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On April 10, 2006, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 9,500 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on April 11, 2006.
Outlook, Risks, and Management Commentary
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees. No specific guidance, risks, or unusual items regarding financial performance are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust prior to the April 10, 2006 transfer.
- Confirm the specific number of shares allocated to each participant in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance regarding director interests.